

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Mylan Pharmaceuticals Inc.

v.

Patent Owner

Patent No. 8,399,413

IPR2015-00644

**CORRECTED DECLARATION OF STEPHEN J. PEROUTKA,
M.D., PH.D.**

TABLE OF CONTENTS

| | | |
|-------------|--|----|
| I. | QUALIFICATIONS AND BACKGROUND | 4 |
| A. | Education and Experience..... | 4 |
| B. | Materials Considered..... | 9 |
| C. | Scope of Work..... | 9 |
| II. | SUMMARY OF OPINIONS | 10 |
| III. | LEGAL STANDARDS | 17 |
| IV. | PRIORITY DATE | 20 |
| V. | PERSON OF ORDINARY SKILL IN THE ART | 21 |
| VI. | BACKGROUND OF GLATIRAMER ACETATE | 22 |
| VII. | PRIOR ART GLATIRAMER ACETATE DOSING STUDIES | 25 |
| A. | Overview of Dose Range Studies..... | 25 |
| B. | Early Dosing Studies of Glatiramer Acetate Established a Minimum Effective Dosing in Multiple Sclerosis (5 mg 5 times per week or 25 mg/week)..... | 28 |
| C. | A Clinically Effective Dose of GA for Treating MS Has Been Known Since 1984 (20 mg Daily Dosing or 140 mg/week)..... | 29 |
| D. | Flechter 2002 (A & B) and Khan 2008: Alternate Day Dosing of GA 20 mg Effective to Treat MS (60 to 80 mg/week)..... | 32 |
| E. | Cohen 2007: 40 mg Daily Dosing of Glatiramer Acetate (i.e., 280 mg per week) Also Effective to Treat MS (i.e. 280 mg/week) | 39 |
| F. | Rasmussen 2005 Every Other Day and Three Times Per Week Dosing in the Treatment of MS (preferably 10-40 mg GA every 48 hours or 30-120 mg GA per week) | 40 |

| | | |
|--------------|---|-----------|
| G. | Pinchasi 2007: Every Other Day Dosing of 40 mg GA (i.e., 120 or 160 mg GA per 7-Day Period) Effective to Treat MS | 42 |
| H. | Summary of Prior Art Teaching of Dosing Ranges and Frequency | 45 |
| VIII. | THE MAJORITY OF THE '413 PATENT'S CLAIMS ARE ANTICIPATED BY PINCHASI 2007 | 48 |
| A. | Independent Claim 1 of the '413 Patent Is Disclosed in Pinchasi 2007 | 48 |
| 1. | “reducing the frequency of relapses in a human patient suffering from relapsing-remitting multiple sclerosis” | 49 |
| 2. | “comprising administering to the human patient a therapeutically effective dosage regimen of three subcutaneous injections of 1 ml of a pharmaceutical composition comprising 40 mg of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection” | 49 |
| 3. | “the regimen being sufficient to reduce the frequency of relapses in the patient.” | 51 |
| B. | Dependent Claims 2, 3, 5, 8, 12 and 13 of the '413 Patent Are Disclosed in Pinchasi 2007 | 51 |
| C. | Dependent Claims 4, 6 and 9-11 Are Disclosed in Pinchasi 2007 | 54 |
| D. | Dependent Claims 14-18 Are Disclosed in Pinchasi 2007 | 56 |
| E. | Independent Claim 19 Is Disclosed in Pinchasi 2007..... | 62 |
| F. | Independent Claim 20 of the '413 Patent Is Disclosed in Pinchasi 2007 | 62 |
| IX. | EACH CLAIM OF THE '413 PATENT IS INVALID AS OBVIOUS | 63 |
| A. | Overview of Petitioner's Obviousness Challenge | 63 |

| | | |
|-----------|---|------------|
| B. | Compliance, Side Effect, and Commercial Considerations Motivated Less Frequent GA Dosing | 66 |
| 1. | Patient Compliance | 66 |
| 2. | Side Effects of Daily Injections | 68 |
| 3. | Financial and Market Forces..... | 71 |
| C. | The Prior Art Provides a Reasonable Expectation of Success in Administering the Claimed Dosing Regimen | 73 |
| D. | Pinchasi 2007, Alone or in View of the 1996 FDA SBOA Renders Each Claim of the '413 Patent Obvious..... | 76 |
| E. | Each Claim of the '413 Patent is Obvious over Pinchasi 2007 in view of Flechter 2002A..... | 89 |
| 1. | Claim 1 of the '413 Patent Is Obvious..... | 90 |
| 2. | Claims 2, 3, 5, 8, 12 and 13 of the '413 Patent Are Obvious | 93 |
| 3. | Claims 4, 9-11 Are Obvious | 95 |
| 4. | Claim 6 of the '413 Patent Is Obvious..... | 96 |
| 5. | Claim 7 of the '413 Patent Is Obvious..... | 97 |
| 6. | Claim 16 of the '413 Patent Is Obvious..... | 100 |
| 7. | Claims 14 and 17 of the '413 Patent Are Obvious | 103 |
| 8. | Claims 15 and 18 of the '413 Patent Are Obvious | 105 |
| 9. | Claim 19 of the '413 Patent | 108 |
| 10. | Claim 20 of the '413 Patent | 109 |
| X. | CONCLUSION | 111 |

I. QUALIFICATIONS AND BACKGROUND

A. Education and Experience

1. My name is Stephen J. Peroutka. I am a physician and pharmacologist with over thirty years of experience. Throughout my career I have practiced as a clinician in the field of neurology, conducted research in multiple neurological disorders, including multiple sclerosis (MS)¹, and held a number of relevant positions in the biotechnology and pharmaceutical industries. My full *curriculum vitae* (CV) is attached hereto as Exhibit A and is incorporated herein.

2. I received my A.B. degree in neurobiology and psychology from Cornell University in 1975, where I was a College Scholar in the School of Arts and Sciences and graduated Phi Beta Kappa. In 1979, I received an M.D. degree from the Johns Hopkins University School of Medicine. I earned my Ph.D. from the Department of Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in 1980.

3. I currently serve as Chief Medical Officer of Semnur Pharmaceuticals,

¹ In this declaration, I use several abbreviations for certain well known terminology in the art, including for example “MS” for multiple sclerosis, “RRMS” for relapse-remitting multiple sclerosis, “GA” for the glatiramer acetate active ingredient, and “SC” for the subcutaneous route of injection.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.